[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2017

US$ 2,000.00

... Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

December 2017 30 pages

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017

US$ 3,500.00

... 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 50 pages

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2017

US$ 3,500.00

... Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 40 pages

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H2 2017

US$ 3,500.00

... Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 33 pages

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

US$ 3,500.00

... Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 25 pages

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape Develop and design ...

December 2017 48 pages

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) development landscape Develop and design ...

December 2017 28 pages

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H2 2017

US$ 3,500.00

... Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 36 pages

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H2 2017

US$ 3,500.00

... Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 42 pages

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H2 2017

US$ 3,500.00

... Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 62 pages

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H2 2017

US$ 3,500.00

... Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 65 pages

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017

US$ 3,500.00

... Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 51 pages

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2017

US$ 3,500.00

... Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 50 pages

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Pipeline Review, H2 2017

US$ 3,500.00

... Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 26 pages

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2017

US$ 3,500.00

... Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 110 pages

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2017

US$ 3,500.00

... Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development ...

December 2017 83 pages

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) development landscape Develop and ...

December 2017 45 pages

Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H2 2017

US$ 3,500.00

... Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 37 pages

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development ...

December 2017 58 pages

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development ...

December 2017 58 pages

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2017

US$ 3,500.00

... type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics development with respective active and ...

December 2017 44 pages

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H2 2017

US$ 3,500.00

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Pro...

December 2017 30 pages

Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

US$ 2,500.00

... releases. The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

December 2017 2678 pages

Colon Cancer - Pipeline Review, H2 2017

US$ 2,500.00

... releases. The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

December 2017 773 pages

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017

US$ 2,000.00

... . The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

December 2017 35 pages

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape Develop ...

November 2017 53 pages

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2017

US$ 3,500.00

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape Develop and design in-licensing and ...

November 2017 65 pages

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape Develop and design ...

November 2017 43 pages

Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Pipeline Review, H2 2017

US$ 3,500.00

... also reviews key players involved in Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics development with respective ...

November 2017 51 pages

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) development landscape Develop ...

November 2017 22 pages

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H2 2017

US$ 3,500.00

... Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 51 pages

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H2 2017

US$ 3,500.00

... Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 51 pages

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H2 2017

US$ 3,500.00

... Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 73 pages

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H2 2017

US$ 3,500.00

... T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 67 pages

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape Develop and design ...

November 2017 44 pages

Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017

US$ 3,500.00

... Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 30 pages

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2017

US$ 3,500.00

... TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

November 2017 31 pages

Q Fever - Pipeline Review, H2 2017

US$ 2,000.00

... . The Q Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

November 2017 36 pages

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017

US$ 2,000.00

... . The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

October 2017 66 pages

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017

US$ 3,500.00

... Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

October 2017 38 pages

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) development landscape Develop and ...

October 2017 35 pages

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2017

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape Develop and design ...

October 2017 38 pages

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2017

US$ 2,000.00

... ’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. The guide covers therapeutics under ...

September 2017 60 pages

Liver Fibrosis - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

September 2017 216 pages

Cachexia - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

September 2017 42 pages

Fibrosis - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

September 2017 122 pages

Dupuytren Contracture - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dupuytren Contracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

September 2017 31 pages

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Hepatic - Colorectal Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatic - Colorectal Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

September 2017 39 pages

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) development landscape ...

August 2017 25 pages

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) development ...

August 2017 48 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

Date

Pages

Offers